NeuroTherapeutics Pharma, Inc., a Chicago, IL-based biopharmaceutical company focused on developing novel therapies for central nervous system disorders, received a $100,000 investment from the Epilepsy Therapy Project.
NeuroTherapeutics Pharma is backed by Novo Ventures and Thomas, McNerney and Partners and is currently raising its Series B financing, which will advance NTP-2014 through multiple proof-of-concept Phase II trials and further develop a pipeline to expand this new class of therapy.
The Epilepsy Therapy Project, a non-profit organization whose mission is to accelerate ideas into therapies for people living with epilepsy and seizures, invests in promising research efforts in order to help make new therapies a reality for patients.
FinSMEs
10/11/2009